We believe that systematic implementation of immunohistochemistry for ER, PR and HER2 could substantially improve the diagnostic work-up of pure DCIS, at the very least in clinical trials, but preferentially in routine practice too. This evidence concerns the gene ESR1 and ductal breast carcinoma in situ.